Navigation Links
Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Date:3/31/2008

Two oral presentations, two poster discussion presentations, three poster

presentations

SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that data from clinical trials of the company's investigational compounds XL647, XL184, XL765 and XL880 will be presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30 to June 3, 2008 in Chicago, Illinois. The clinical trial data will be described in two oral presentations (XL184 and XL765), two poster presentations and discussions (XL647), and three poster presentations (XL647 and XL880).

Oral Presentations

-- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in

patients with advanced malignancies, including medullary thyroid

cancer, will be presented on Sunday, June 1, 2008, starting at 10 a.m.

local time (Abstract #3522).

-- XL765 (PI3K, mTOR). Data from a phase 1 trial of XL765 in patients

with advanced solid tumors will be presented on Saturday, May 31,

2008, starting at 1:15 p.m. local time (Abstract #3510).

Poster Presentations and Discussions

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in

NSCLC patients with acquired resistance to EGFR tyrosine kinase

inhibitors will be presented on Monday, June 2, 2008, during the 8

a.m.-noon session (Abstract #8028).

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 1 trial of XL647 dosed

daily in patients with advanced solid malignancies will be presented

on Saturday, May 31, 2008, during the 8 a.m.-noon session (Abstract


'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
2. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
3. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
4. MedImmune Announces Seven Key Promotions and New Hires
5. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
8. Jarrow Formulas Launches New Products Featuring BioCell Collagen II(R)
9. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
10. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... An international research team including DESY scientists has observed ... The team reports in the journal Science ... lattices inside the nanodroplets. It is the first time ... in larger samples of what is known as superfluid ... exceeded our best expectations," says Andrey Vilesov of the ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014 ... launch of their Nutraceutical "TELO-20 for Dogs" with ... only Telomere-lengthening supplement in the world for dogs. ... of every chromosome in the body. A wealth ... leading experts in Telomere Science and Aging, including ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... commentary with Michael J. Cronin, Ph.D., J.D., an intellectual property ... look at the facts in the dispute over three important ... the history behind similar disputes - shows a strong likelihood ... all of its patent rights, even if some of its ...
... writing a series of articles on raising capital from investors. This ... of the time when raising equity capital, the offering terms are ... . When dealing with angel investors , it is ... ,Sometimes prospective angel investors will want to negotiate the initial term ...
... who once said everyone will be famous for 15 minutes, couldn't ... might have on his prediction. , ,With these tools, everyone can ... even that. It seems that 15 minutes is about all anyone ... of Silicon Valley. , ,I was reminded of this after ...
Cached Biology Technology:WARF is likely to hold on to stem cell patent rights 2WARF is likely to hold on to stem cell patent rights 3WARF is likely to hold on to stem cell patent rights 4WARF is likely to hold on to stem cell patent rights 5WARF is likely to hold on to stem cell patent rights 6WARF is likely to hold on to stem cell patent rights 7WARF is likely to hold on to stem cell patent rights 8Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
(Date:8/21/2014)... Oct. 18-22, 2014 , WHERE: , San ... Diego, CA 92101 , WHAT: , Invited ... the latest research in human genetics. Examples of ... abstracts on rare genetic variants in health and ... for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... and vegetables is a new, patented technology in which a ... "etch" information on produce, thereby eliminating the need for common ... a variety of fruits and vegetables and is being used ... been been approved in Asia, South Africa, Central and South ...
... of Illinois at Chicago have received $1 million from ... the relationship between "fat taxes" and food consumption, diet ... project was made available through the American Recovery and ... state tax rates associated with restaurants and with specific ...
... If a circadian rhythm is like an orchestra the united ... chemical may serve as the conductor, or at least as the ... ), the active ingredient in color safe bleach. Produced in all ... active and resting phases of living things, new research by USC ...
Cached Biology News:Laser etching safe alternative for labeling grapefruit 2UIC receives $1 million grant to study 'fat taxes,' diet, obesity 2Not just bleach: Hydrogen peroxide may tell time for living cells 2Not just bleach: Hydrogen peroxide may tell time for living cells 3
HLA-DRbeta (DA2)...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
...
Aldolase A (N-15)...
Biology Products: